Drug
Burosumab
Burosumab: highest development phase Phase 3, developed by Kyowa Kirin, Ultragenyx Pharmaceutical. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Kyowa Kirin, Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| Burosumab NCT03581591 | Phase 3 | Hypophosphatemia |
| Burosumab NCT04695860 | Phase 3 | X-linked Hypophosphatemia |
| burosumab NCT02915705 | Phase 3 | X-Linked Hypophosphatemia |
| burosumab NCT02163577 | Phase 2 | X-linked Hypophosphatemia |
Latest
No recent events.
Follow Burosumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.